BIND Profile
BIND Therapeutics, Inc. was a biotechnology company based in Cambridge, Massachusetts, USA. The company focused on developing targeted and programmable therapeutics for the treatment of cancer and other serious diseases. BIND's technology platform was based on proprietary technology called Accurin, which was designed to enable the precise targeting and controlled release of drugs to specific cells in the body.
The company was founded in 2006 and went public in September 2013. It raised over $130 million in funding from investors including Polaris Partners, Flagship Ventures, ARCH Venture Partners, and NanoDimension. In addition, the company had partnerships with pharmaceutical companies such as Pfizer, AstraZeneca, and Roche.
However, despite its promising technology and partnerships, BIND faced financial difficulties and was unable to meet its debt obligations. In May 2016, the company filed for Chapter 11 bankruptcy and announced that it had entered into an agreement to sell its assets to Pfizer for $20 million. The sale was completed in June 2016, and BIND ceased to exist as an independent entity.
BIND's Accurin technology platform was subsequently integrated into Pfizer's drug discovery and development efforts, and several Accurin-based drug candidates are currently in preclinical and clinical development.
|
